- Home
- USIO vs KYNB Comparison
USIO vs KYNB Comparison
Compare USIO & KYNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | USIO | KYNB |
|---|---|---|
| Founded | 1998 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.6M | 31.9M |
| IPO Year | 1999 | N/A |
Fundamental Metrics
Financial Performance| Metric | USIO | KYNB |
|---|---|---|
| Price | $1.30 | $7.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.00 | N/A |
| AVG Volume (30 Days) | 32.3K | ★ 37.0K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 700.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $28,200,535.00 | N/A |
| Revenue This Year | $6.30 | N/A |
| Revenue Next Year | $11.86 | N/A |
| P/E Ratio | ★ N/A | $0.15 |
| Revenue Growth | ★ 12.69 | N/A |
| 52 Week Low | $1.24 | $6.67 |
| 52 Week High | $2.02 | $9.58 |
Technical Indicators
Market Signals| Indicator | USIO | KYNB |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 46.67 |
| Support Level | N/A | $7.37 |
| Resistance Level | $1.42 | $8.89 |
| Average True Range (ATR) | 0.04 | 0.49 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 10.53 | 30.60 |
Price Performance
Historical ComparisonAbout USIO Usio Inc.
Usio Inc is a United States-based company that provides integrated electronic payment services, including credit and debit card-based processing services and transaction processing via the Automated Clearing House, or ACH network to billers and retailers. The Company also has an additional wholly-owned subsidiary, which is the entity for Output Solutions operations.
About KYNB Kyntra Bio Inc. Common Stock
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.